The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab

Yoshimura, Akihiro; Nagahara, Akira; Ishizuya, Yu; Yamamoto, Yoshiyuki; Hatano, Koji; Kawashima, Atsunari; Nakai, Yasutomo; Nakayama, Masashi; Nishimura, Kazuo; Nonomura, Norio; Kato, Taigo

doi:https://doi.org/10.1007/s10238-024-01370-8

The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab

Yoshimura, Akihiro; Nagahara, Akira; Ishizuya, Yu et al.

Clinical and Experimental Medicine, 2024, 24, 111

Number of Access:1,992（2025-10-12 09:48 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/97122

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
ClinExpMed_24_111	pdf	None	880 KB	84	2024.07.05

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab
Creator	NRID 1000070981992 1000070981992 CreatorName Yoshimura, Akihiro
	NRID 1000090588774 1000090588774 CreatorName Nagahara, Akira
	NRID 1000000783854 1000000783854 researchmap permalink okiishi okiishi CreatorName Ishizuya, Yu
	NRID 1000090759557 1000090759557 researchmap permalink yoshi229 yoshi229 ORCID 0000-0002-1271-3521 0000-0002-1271-3521 CreatorName Yamamoto, Yoshiyuki
	NRID 1000060762234 1000060762234 researchmap permalink koji_hatano koji_hatano Scopus Author ID 14627167600 14627167600 CreatorName Hatano, Koji
	NRID 1000050746568 1000050746568 researchmap permalink akawashima akawashima Scopus Author ID 9846139400 9846139400 CreatorName Kawashima, Atsunari
	CreatorName Nakai, Yasutomo
	NRID 1000040379178 1000040379178 CreatorName Nakayama, Masashi
	NRID 1000080303957 1000080303957 CreatorName Nishimura, Kazuo
	NRID 1000030263263 1000030263263 researchmap permalink read0185096 read0185096 Scopus Author ID 7005880662 7005880662 CreatorName Nonomura, Norio
	NRID 1000070648021 1000070648021 researchmap permalink taigokato taigokato Scopus Author ID 55414697500 55414697500 ORCID 0000-0002-8681-1407 0000-0002-8681-1407 CreatorName Kato, Taigo
Subject	Eosinophil
	Immune checkpoint inhibitor
	Immune-related adverse event
	Renal cell carcinoma
Description	The version of record of this article, first published in Clinical and Experimental Medicine, is available online at Publisher’s website: https://doi.org/10.1007/s10238-024-01370-8.
Abstract	Although immune checkpoint inhibitors (ICIs) have gained approval for metastatic renal cell carcinoma (mRCC), the response rate is still limited. Therefore, it is urgent to explore novel markers of responses to ICIs that can help assess clinical benefits. Recently, it has been noted that peripheral blood eosinophil counts are an independent factor correlated with clinical outcome of ICIs in some types of cancer. We investigated peripheral blood absolute eosinophil counts (AECs) at baseline and 4 weeks after the initiation of nivolumab for mRCC patients between February 2016 and May 2022. In addition, we examined clinicopathological features including irAEs and analyzed the correlation between AECs and clinical efficacy of nivolumab. The median progression-free survival (PFS) and overall survival (OS) for all patients were 5.7 and 25.5 months, respectively. The median AECs in patients with irAEs were significantly higher at baseline and 4 weeks after the treatment compared to those without irAEs (p < 0.001 and p = 0.001). With the cutoff value of AECs of 329 cells/µL at 4 weeks after the treatment for prediction of irAEs, high-AECs groups had significantly higher number of responders compared with that in low-AECs group (p < 0.001). Accordingly, the PFS and OS were significantly better in patients with high-AECs group than those in low-AECs group (p = 0.03 and p = 0.009). High-AECs at 4 weeks after the treatment serve as the prominent surrogate marker associated with the incidence of irAEs and better clinical outcome in mRCC patients receiving nivolumab.
Publisher	Springer Science and Business Media Deutschland GmbH
Source Title	Clinical and Experimental Medicine
Volume (Issue)	24
Page	111
Date of Issued	2024-05-23
Language	English
Handle URL	https://hdl.handle.net/11094/97122
PISSN	15918890
eISSN	15919528
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1007/s10238-024-01370-8
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCTERMS.bibliographicCitation	Clinical and Experimental Medicine. 2024, 24, p. 111
DC.title	The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab
DC.creator	Yoshimura, Akihiro
	Nagahara, Akira
	Ishizuya, Yu
	Yamamoto, Yoshiyuki
	Hatano, Koji
	Kawashima, Atsunari
	Nakai, Yasutomo
	Nakayama, Masashi
	Nishimura, Kazuo
	Nonomura, Norio
	Kato, Taigo
DC.publisher	Springer Science and Business Media Deutschland GmbH
DC.language' scheme='DCTERMS.RFC1766	English
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-05-23
DC.identifier	https://doi.org/10.1007/s10238-024-01370-8
DC.subject	Eosinophil
	Immune checkpoint inhibitor
	Immune-related adverse event
	Renal cell carcinoma
DC.description	The version of record of this article, first published in Clinical and Experimental Medicine, is available online at Publisher’s website: https://doi.org/10.1007/s10238-024-01370-8.
DCTERMS.abstract	Although immune checkpoint inhibitors (ICIs) have gained approval for metastatic renal cell carcinoma (mRCC), the response rate is still limited. Therefore, it is urgent to explore novel markers of responses to ICIs that can help assess clinical benefits. Recently, it has been noted that peripheral blood eosinophil counts are an independent factor correlated with clinical outcome of ICIs in some types of cancer. We investigated peripheral blood absolute eosinophil counts (AECs) at baseline and 4 weeks after the initiation of nivolumab for mRCC patients between February 2016 and May 2022. In addition, we examined clinicopathological features including irAEs and analyzed the correlation between AECs and clinical efficacy of nivolumab. The median progression-free survival (PFS) and overall survival (OS) for all patients were 5.7 and 25.5 months, respectively. The median AECs in patients with irAEs were significantly higher at baseline and 4 weeks after the treatment compared to those without irAEs (p < 0.001 and p = 0.001). With the cutoff value of AECs of 329 cells/µL at 4 weeks after the treatment for prediction of irAEs, high-AECs groups had significantly higher number of responders compared with that in low-AECs group (p < 0.001). Accordingly, the PFS and OS were significantly better in patients with high-AECs group than those in low-AECs group (p = 0.03 and p = 0.009). High-AECs at 4 weeks after the treatment serve as the prominent surrogate marker associated with the incidence of irAEs and better clinical outcome in mRCC patients receiving nivolumab.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	97122
citation_title	The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab
citation_author	Yoshimura, Akihiro
	Nagahara, Akira
	Ishizuya, Yu
	Yamamoto, Yoshiyuki
	Hatano, Koji
	Kawashima, Atsunari
	Nakai, Yasutomo
	Nakayama, Masashi
	Nishimura, Kazuo
	Nonomura, Norio
	Kato, Taigo
citation_publisher	Springer Science and Business Media Deutschland GmbH
citation_language	English
citation_date	2024-05-23
citation_journal_title	Clinical and Experimental Medicine
citation_volume	24
citation_firstpage	111
citation_doi	https://doi.org/10.1007/s10238-024-01370-8
citation_public_url	https://hdl.handle.net/11094/97122

The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab

Link to primary information

Item Information

Show details